Comparative Pharmacology
Head-to-head clinical analysis: ROZEREM versus TASIMELTEON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ROZEREM versus TASIMELTEON.
ROZEREM vs TASIMELTEON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective melatonin receptor agonist with high affinity for MT1 and MT2 receptors in the suprachiasmatic nucleus; modulates circadian rhythm and sleep-wake cycle.
Tasimelteon is a selective melatonin MT1 and MT2 receptor agonist that mimics the natural sleep-promoting effects of melatonin by modulating circadian rhythms. It binds to MT1 receptors to promote sleep onset and to MT2 receptors to phase-shift the circadian clock.
8 mg orally once daily, 30 minutes before bedtime, not to exceed 8 mg per day.
20 mg orally once daily at bedtime, taken within 30 minutes of retiring and at the same time each night. Not to be taken with or immediately after a high-fat meal.
None Documented
None Documented
Clinical Note
moderateTasimelteon + Ketoconazole
"The serum concentration of Ketoconazole can be increased when it is combined with Tasimelteon."
Clinical Note
moderateTasimelteon + Venlafaxine
"The risk or severity of adverse effects can be increased when Tasimelteon is combined with Venlafaxine."
Clinical Note
moderateTasimelteon + Atazanavir
"The serum concentration of Atazanavir can be increased when it is combined with Tasimelteon."
Clinical Note
moderateTasimelteon + Clarithromycin
Ramelteon: 1-2.6 hours. Active metabolite M-II: 2-5 hours. Clinical context: Short half-life supports use for sleep initiation without significant next-day residual effects.
1.3 hours (range 0.5–2.0 h); short half-life consistent with use for sleep initiation without residual sedation.
Primarily renal (about 84% of total clearance), with approximately 70-80% of an oral dose excreted in urine as glucuronide conjugates of ramelteon and its active metabolite M-II. Fecal excretion accounts for about 4%.
Primarily hepatic metabolism via CYP1A2 and CYP3A4; <0.1% excreted unchanged in urine; fecal excretion accounts for ~80% of total clearance as metabolites.
Category C
Category C
Melatonin Receptor Agonist
Melatonin Receptor Agonist
"The serum concentration of Clarithromycin can be increased when it is combined with Tasimelteon."